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Abstract 
Purpose: Treatments for colorectal cancer(CRC) include surgery, chemotherapy and radiotherapy and each impacts 
on a patient’s quality-of-life. Randomised controlled trials(RCTs) are the most robust study design measuring 
outcomes of CRC treatments, but to influence clinical practice trial design and reporting of patient reported 
outcomes (PROs) must be of high quality. The primary objective was to examine the quality of PRO reporting in 
RCTs of CRC treatment. Secondary objectives were to assess the availability of robust data to inform clinical 
decision-making and to investigate whether quality of reporting improved over time.  
Methods: A systematic review from January 2004-February 2012 identified RCTs of CRC treatment describing PROs. 
Relevant abstracts were screened and manuscripts obtained. Methodological quality was assessed using ISOQOL-
PRO (International Society for Quality of Life Research-Patient Reported Outcome) reporting standards. Trials 
meeting at least two-thirds of these criteria were classified as high-quality. Changes in reporting quality over time 
were established by comparison with previous data and risk of bias was assessed with the Cochrane Risk of Bias tool.  
Results:66 RCTs were identified, seven studies(10%) reported survival benefit favouring the experimental treatment, 
35 trials(53%) identified differences in PROs between treatment groups and the significance of these differences was 
discussed in 19 studies(29%). Improvements over time in the documentation/handling of missing data and the 
discussion of the clinical significance of PROs occurred. Thirteen trials(20%) had high-quality reporting of PROs of 
which two trials(3%) also had low-risk of bias.   
Conclusions: While improvements in PRO quality reporting over time were found, several recent studies still fail 
to robustly inform clinical practice. To improve the quality and relevance of RCTs, trial protocols should adhere to 
the SPIRIT recommendations and study reporting must follow the CONSORT statement and PRO extension.  
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What is already known about this subject?  
Randomised controlled trials (RCTs) provide the highest quality evidence regarding the effectiveness of novel 
treatments for colorectal cancer (CRC). 
To fully inform decision making trials should describe both clinical and patient reported outcomes with the most 
rigorous methodological quality.  
Current evidence suggests poor quality outcome reporting in RCTs is common at other tumour sites, but the quality 
of reporting in colorectal cancer trials is unknown. 
What are the new findings? 
Quality of reporting of patient reported outcomes in RCTs of CRC patients has improved over time with regard to 
specific methodological aspects.  
 
CRC Trials that report both clinical and patient reported outcomes with good methodological quality are rare. 
 
Currently few trials in CRC describing clinical and patient reported outcomes will effectively influence clinical practice 
due to the poor quality of reporting.  
 
How might it impact on clinical practice in the foreseeable future? 
Clinicians when designing trials must ensure that trial protocols are prepared following the SPRIT guidance, that 
reporting follows the CONSORT recommendations including the patient reported outcomes extension and the 
relevance of both clinical and patient reported outcomes are described in trial reports. 
Clinicians must ensure when reviewing reports of RCTs they are aware of the need for high quality reporting of PROs 
and clinical outcomes so that the trial findings can be used in daily practice.  
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Introduction 
Well designed and conducted randomised controlled trials (RCTs) can provide the highest quality evidence for novel 
cancer therapies(Sibbald and Roland 1998). Traditional outcomes include overall or progression free survival, 
complications such as infection and side effects of chemo- or radiotherapy. In recent years trials have incorporated 
the patients’ perspective describing patient reported outcomes (PROs). A number of guidelines for reporting PROs 
in RCTs have been proposed in the last two decades(Efficace et al. 2003; Lee and Chi 2000; Staquet et al. 1996)  and 
more recently these recommendations have been updated by the International Society for Quality of Life Research 
(ISOQoL) and incorporated as a PRO extension to the CONSORT (Consolidated Standards of Reporting Trials) 
statement.  Despite this guidance evidence suggests that clinicians find interpreting PROs difficult(Greenhalgh 2009). 
Many RCTs fail to explain the relevance of PROs to the overall trial findings and often do not incorporate PROs into 
subsequent treatment recommendations(Cocks et al. 2008). If trials are to influence clinical care they must be of 
high quality, consistently report both clinical and patient reported outcomes, and base treatment recommendations 
on all relevant outcomes. This is particularly important when treatments may have different impacts on clinical and 
PROs, for worsening global quality of life (QoL) and symptoms but improved long term survival. Fully understanding 
the overall effect of a novel therapy on both patient reported and clinical outcomes will allow the clinician and 
patient to consider differing treatment effects and make decisions that trade off survival, symptoms, functional 
abilities and QoL during shared decision-making   
Colorectal cancer is common worldwide (J et al. 2010; UK 2009) and although survival rates of 60% at 5 years are 
often achieved using a combination of surgery, pre-operative radiotherapy and post-operative chemotherapy 
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(Coleman et al. 2011), functional deficits and severe symptoms due to these treatments are common. Problems 
related to bowel habit and sexual / urinary dysfunction are often reported in rectal cancer(Gujral et al. 2008). 
Fatigue, pain and reduced activity are common(Denlinger and Barsevick 2009; Thong et al. 2013) and problems with 
adaption to life with a stoma are frequently described(Peeters et al. 2005). The consequences of this disease and its 
subsequent treatment will impact upon a large number of survivors and patients should be provided with the highest 
quality and most accurate information regarding optimal treatments and their effects on clinical and patient 
reported outcomes.  Information about the detrimental effects of treatment on functional abilities, QOL and 
symptoms will help inform patients about the anticipated effects of treatment and help inform decision making. 
However, current evidence synthesis of RCTs describing colorectal cancer treatments that include both clinical and 
patient reported outcomes is limited (de Kort et al. 2006; Gujral et al. 2008). In a previous systematic review of 
colorectal PRO-RCTs studies published between 1980 and 2003, a number methodological limitations were 
highlighted which hampered critical appraisal of the PRO findings(Efficace et al. 2004)  
The objective of this systematic review is to identify RCT’s in colorectal cancer that report clinical and PROs and 
determine the quality of PRO reporting. Secondary objectives are to document the characteristics of the included 
studies, document the PRO tools used, record the effect of the experimental treatment on both clinical and PROs 
assess whether the reporting of key methodological aspects of PROs has improved over time and describe those 
studies most likely to robustly inform clinical decision making. 
 
Methods 
Identification of studies 
Systematic literature searches were undertaken between January 2004 and February  2012 using the OVID 
Gateway™ (http://ovidsp.ovid.com/) to access Medline, CINHAL, PsychInfo and the Cochrane Controlled Trials 
Register using an optimized highly sensitive search strategy.  Inclusion criteria were: RCTs enrolling at least 50 
patients in total, with participants in the RCTs aged 18 years or older; diagnosed and treated for colorectal cancer 
 7 
 
(studies on anal cancer also considered eligible); treated with surgery, chemotherapy, radiotherapy or biological 
treatments; assessments including PROs, either as a primary or secondary endpoint. Only RCTs enrolling at least 50 
patients, overall, were included as those with smaller samples were considered too limited to provide adequately 
powered PRO analyses.  
If a second publication, related to the main RCT, highlighting additional details regarding PROs was identified then 
the full text of this additional manuscript was also obtained. Studies reporting complementary, alternative or 
psychological interventions and those describing proxy-based questionnaires (i.e. completed by clinicians or other 
observers) were excluded. The results were reported according to the PRISMA guidelines(Liberati et al. 2009). 
Relevant data were independently extracted by two reviewers to a standardised data extraction e-form hosted on a 
secure server with a password protected database (http://promotion.gimema.it/). Supporting or additional 
publications directly relevant to the included RCTs were also examined. In face to face meetings when disagreement 
between reviewers occurred the relevant trial manuscript was reviewed jointly by the two reviewers (VC and KW) 
and differences reconciled until consensus on the extracted data was achieved. If consensus could not be achieved 
then a third independent reviewer was consulted (FE). 
Study characteristics and PRO tools used 
Details of the study design, the number of participants and their demographics, the study location (national or 
international), whether the study was performed by a co-operative group and if industry had a role in any funding 
were recorded. Information describing the disease stage “curable/local” or “advanced/metastatic” was noted. 
Details of the interventions or treatments employed in the control and experimental arm of the RCT were recorded 
and information describing each outcome assessed in the trial was entered into the database including details of 
which outcome constituted the primary end-point of the trial. When an end-point was patient reported, details of 
the PRO tool used to make the assessment were noted.  
Effect of experimental intervention on clinical and patient reported outcomes 
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The effect of the experimental intervention on PROs was recorded and this was classified as an effect on symptoms 
alone, domains other than symptoms (functional scales and global quality of life) or both symptoms and other 
domains. 
Quality of reporting of PROs and assessment of bias 
Based on previous work(Efficace et al. 2013), the quality of PRO reporting was assessed by comparison with the 
criteria of the ISOQoL reporting standards(Brundage et al. 2012). For studies where PROs were the primary outcome  
29 criteria of the reporting standards were applicable whilst only 18 criteria apply to trials where PROs were a 
secondary outcome(Brundage et al. 2012).  A score of 1 was allocated to a study if a relevant reporting standard was 
met, and 0 if it was not met. Therefore in studies where PROs were a primary end point a maximum score of 29 
points could be achieved whilst a reduced maximum score of 18 points was possible for trials where PROs were a 
secondary endpoint. Studies were considered to have “high quality PRO reporting”, based on previously defined 
criteria (Efficace et al 2013).  Study bias was assessed using the Cochrane risk of bias tool specifically assessing 
adequacy of trial sequence generation, allocation concealment, blinding of trial patients and staff, blinding of 
outcome assessment, incomplete outcome data, selective outcome reporting and any other potential sources of 
bias (Higgins JPT 2011).  
Assessment of changes in PRO reporting quality over time 
Differences over time in the frequency of reporting of key PRO quality criteria (A priori hypothesis stated, rationale 
for the instrument reported, method of instrument administration reported, timing of the PRO assessments 
documented, missing data documented, statistical approaches for handling missing data recorded and clinical 
significance addressed) across the studies were determined by comparison with previously published data(Efficace 
et al. 2004). 
Analysis of outcomes reporting, availability of robust data to inform decision-making and summary of studies with 
high quality PRO reporting  
 9 
 
For trials with “high quality PRO reporting” details of the main clinical outcomes and PROs were recorded, the results 
of the trials summarised and the data available to inform decision making described. Trials with the greatest 
generalizability and those with the lowest risk of bias were further highlighted. In case of studies using multiple PRO 
measures, these were still rated as “using PRO validated measures” if at least one of the PRO measures used was 
validated.  
Data analysis 
Findings are reported using descriptive statistics. It was specified that PROs from included studies would be 
synthesised in a meta-analysis using a random effects model(Hedges and Olkin 1985) only if sufficient studies using 
consistent PRO measurements were identified.  All analyses were performed with SAS Version 9.2 (SAS Institute Inc., 
Cary, NC, USA).  
 
Results 
Identification of studies 
4978 abstracts were screened, 292 full text manuscripts were retrieved and 66 RCT’s were identified (Figure 1), 
enrolling overall 36367 patients. In addition a further 63 manuscripts providing additional information regarding the 
included RCT’s were obtained. 
 
Study characteristics and PRO measures   
Details of study characteristics are reported in table 1. Patient reported outcomes were primary endpoints in 12/66 
(18%) studies of which three (25%) were carried out in a multinational context and three (25%) were at least partially 
supported by industry. Six (50%) studies involved patients with localised disease, two (17%) studies with advanced 
or metastatic disease, and four (33%) studies included patients both localised and advanced disease. In all 66 studies 
the most commonly reported treatment type was chemotherapy (n=45; 68%) with smaller numbers of trials 
describing outcomes after surgery (n=19; 29%), targeted therapy (n=12; 18%) or radiotherapy (n=9; 14%). A number 
of studies included two or more treatment modalities. PROs were most commonly assessed with the EORTC QLQ-
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C30 questionnaire (n=31; 47%). The remaining studies used either the Functional Assessment of Cancer Therapy 
questionnaire (n=8; 12%), bespoke visual analogue scales (n=11; 17%), or a number of other tools including the SF-
36 and EQ-5D (n=16; 24%). Twenty nine studies (44%) used more than one PRO measure. 
 
Effects of experimental intervention on clinical and patient reported outcomes 
Half of the included studies (n=33; 50%) showed a difference (in any direction) in the primary endpoint between the 
standard treatment and the experimental treatment groups and seven studies (10%) reported overall survival (OS) 
benefit favouring the experimental treatment. Forty two of the 66 studies that reported OS did not find difference 
between treatment groups. However 20 (48%) of those 42 did show a statistical difference in PROs between groups. 
Overall, a difference in PROs between treatment arms was found in 34 studies (53%), with the majority of these 
studies (n=29/34; 85%) describing PROs that favoured the experimental treatment (table 1).  
 
Quality of reporting of PROs and assessment of bias 
Table 2 documents the extent to which the included studies adequately reported PROs. Overall, only 20 studies 
(30%) stated the method of PRO administration, and most studies did not describe the rationale for choosing the 
PRO instrument used (n=51, 77%). Of the 12 studies where PROs were the primary outcome, five (42%) failed to 
provide a citation for the development or validation of the PRO instrument used and none of the RCTs where PROs 
were a primary outcome provided justification for the timing of when PRO tools were administered. In contrast, the 
validity and reliability of the PRO instrument used was reported in 70% of studies (n=46), and, in addition, most 
studies (90%; n=59) gave details of the time points at which PROs were collected. Statistical approaches for dealing 
with missing data were reported in 18 studies (27%) and just over half the total number of studies (n=37) described 
the extent of missing data. 
A summary of the risk of bias for each RCT, categorised by high or low quality PRO reporting quality is shown in figure 
2. The majority of studies (n=42; 64%) gave details of random sequence generation, whilst in the remaining studies 
the method of random sequence generation could not be ascertained. A smaller proportion of studies adequately 
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described allocation concealment (n=32; 48%), of which only 6 (9%) were classified as having high quality PRO 
reporting.  In the remaining bias domains between 8 and 38 percent of studies with high quality PRO reported had 
high risk of bias. High risk of bias was most commonly detected in the blinding of participants and personnel domain 
for trials with high quality PRO reporting (n=5; 38%), and in the reporting bias domain for trials with low quality PRO 
reporting (n=20; 38%). 
 
Assessment of changes in PRO reporting quality over time 
PRO reporting improved over time from the period 1980-2003 to the period 2004-2012. Details of PRO instrument 
administration were only documented in 10% of studies published up to 2003 whilst this percentage increased to 
30% for included RCTs published between 2004 and 2012. Similarly, documentation of statistical methods for 
handling missing data was found in just 3% of RCTs published up to 2003 but increased to 27% in the present study 
(Figure 3). 
Analysis of outcomes reporting, availability of robust data to inform decision-making and summary of studies with 
high quality PRO reporting  
Thirteen of the 66 studies identified were “high quality” in terms of PRO reporting meeting the pre-defined criteria 
(Supplementary table 3), of which two(Stephens et al. 2010; Stucky et al. 2011) had  consistently low risk of bias in 
all domains and provide influential information that will likely support clinical decision making.  
Thirteen trials (Supplementary table 1) had high quality PRO reporting. Five trials in patients with 
advanced/metastatic disease, six in patients with loco-regional disease and two reported the outcomes of patients 
with CRC of any disease stage. 
In patients with advanced disease two studies (Douillard et al. 2010; Peeters et al. 2010) described the effect of 
adding panitumumab to a chemotherapy regime. This regimes was infusional fluorouracil, leucovorin, and oxaliplatin 
(FOLFOX4; N=1183.)(Douillard et al. 2010)  and fluorouracil, leucovorin, and irinotecan (FOLFIRI; N=1186)(Peeters et 
al. 2010). In both trials, patients in the group receiving panitumumab had longer progression free survival (1-2 
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months) but no difference in PROs was noted. A further study described the effects of panitumumab in in patients 
with chemotherapy refractory metastatic colorectal cancer receiving best supportive care. Those patients receiving 
panitumumab reported improved quality of life if they had normal k-ras genetics but median progression free 
survival irrespective of K-ras status was unaltered(Odom et al. 2011). One study, also in patients with chemotherapy 
refractory metastatic colorectal cancer receiving best supportive care explored the effect of adding cetuximab. 
Cetuximab therapy was associated with improved overall survival and improved physical function and global health 
status particularly in those with wild type K-ras gene expression(Jonker et al. 2007). The final RCT, was a non -
inferiority design, comparing two different modes of administration of adjuvant chemotherapy for CRC, it 
demonstrated that 5-flurouracil and capcitabine was non-inferior to capcitabine and oxaliplatin when objective 
response rate was assessed and quality of life did not differ between the two trial groups(de Kort et al. 2006).    
Six studies described PRO and clinical outcomes in patients with loco-regional disease, of which one RCT reported 
the effects of  different chemotherapy treatments after surgery(Lembersky et al. 2006), one study compared open 
with laparoscopic colorectal surgery (Stucky et al. 2011), two studies described different adjuvant/neo-adjuvant 
radio-chemotherapy regimens for CRC(Stephens et al. 2010; Tournier-Rangeard et al. 2008) and one study the 
administration of granulocyte colony stimulating factor (G-CSF) or placebo  to patients after surgery for 
CRC(Bauhofer et al. 2007).  
Two of the RCTs in patients with loco-regional disease are of particular interest as they had both high quality PRO 
reporting and also consistently low risk of bias(Stephens et al. 2010; Stucky et al. 2011). One described the outcomes 
of short-course pre-operative radiotherapy versus surgery and selective post-operative chemotherapy on QoL in 
patients with rectal cancer (Stephens et al. 2010) using the SF-36 and the EORTC QLQ-C30 questionnaire. A 61% 
reduction in the relative risk of local recurrence with pre-operative radiotherapy (an absolute difference in 
recurrence risk at 3 years of 6.2%) was described and no differences in sexual problems observed between groups. 
Although a good quality trial, it was noted that the limitations of the PRO instruments employed were not discussed 
and recommendations regarding the generalizability of these results to the wider rectal cancer population weren’t 
made. The other high quality trial identified evaluated QoL in patients having open versus laparoscopic colonic 
surgery for the treatment of colorectal cancer (Stucky et al. 2011). This study showed that recurrence of cancer and 
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overall survival were the same in both groups, the duration of post-operative analgesia and length hospital stay was 
shorter in those undergoing laparoscopic surgery and at 18 months post-surgery but patients who had undergone 
laparoscopic-assisted colectomy had significantly greater improvements in global QoL, measures of daily living and 
health compared to the open surgery group.  The largest trial (Lembersky et al. 2006) with high quality reporting 
recruited patients with loco-regional CRC and compared adjuvant leucovorin combined with either oral uracil and 
tegafur or intravenous fluorouracil.  Both overall survival and disease free survival were similar in each group in 
addition no differences in either FACT-C overall scores or subscales were identified. However a statistically 
significant but clinically small difference in scores for the SF-36 questionnaire was identified. 
Two studies recruited patients with any disease stage. One study compared laparoscopic versus open surgery for 
colorectal tumours. Clinical outcomes in each study group were the same but men having laparoscopic rectal surgery 
described worse sexual and erectile functions(Douillard et al. 2010). The other study recruiting patents with all 
disease stages compared early surgery for malignant descending colon obstruction against stent placement followed 
by late surgery(Janson et al. 2007). There were no differences in the clinical outcomes or global quality of life. 
 
Discussion 
This study identified 66 RCT’s enrolling some 36,000 patients from 2004 –2012 reporting clinical and PROs in 
colorectal cancer of which thirteen studies (20%) were considered to have high quality reporting of key 
methodological features of PRO design. Reporting of PRO outcomes is rare in general (only 66 studies over 10 years), 
and high quality reporting methods are uncommon even among studies measuring PROs. These findings suggest 
that high quality RCTs which describe clinical and patient reported outcomes are uncommon and evidence to 
support patient centered decision-making about the optimal treatment for colorectal cancer is lacking.  
The methodological limitations identified in colorectal cancer trials by work have been highlighted in studies 
describing PROs after treatment at other tumour sites including upper gastrointestinal cancer, breast tumours, lung 
malignancy and in reviews incorporating all cancer types (Claassens et al. 2011; Macefield et al. 2013; Ward et al. 
2012; Whistance et al. 2012; Williamson et al. 2012). More recent work describing PRO reporting in RCTs of prostate 
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cancer therapy have also identified similar limitations(Efficace et al. 2013), whilst certain trials in pancreatic cancer 
treatment describe both clinical and patient reported outcomes and make their treatment recommendations 
using both types of outcome(Cunningham et al. 2009) other trials do not take into account PROs when making 
treatment recommendations(Neoptolemos et al. 2010; Richards et al. 2011) . This work also noted that a large 
number of different instruments were used to assess PRO’s, although the majority 60% (n=39) of studies used EORTC 
or FACT questionnaires, significant heterogeneity still existed making study comparison difficult and impairing 
meta-analysis. The issue of heterogeneity in outcome reporting has been highlighted in a number of reviews 
describing outcomes after breast reconstruction(Ward et al. 2012), bariatric surgery(Coulman et al. 2013), 
treatments for oesophageal cancer (Main et al. 2014) and colorectal cancer(Whistance et al. 2013). Consensus on 
the most relevant outcomes for patients and clinicians is necessary and core outcome sets (COS) may provide a 
potential solution to heterogeneity of outcome reporting. A COS an agreed minimum set of outcomes that should 
be measured and reported in all clinical trials of a specific condition, these sets are suitable for both clinical audit 
and research in addition to randomized trials(Williamson et al. 2012). They promote uniformity in outcome reporting 
and facilitate systematic review and meta-analysis. The development of core outcome sets is promoted by COMET 
(Core Outcome Measures in Effectiveness Trials; http://www.comet-initiative.org/) which supports the application 
of agreed standardised core outcome sets and recent work has highlighted methods that select and integrate PROs 
into core outcome sets(Macefield et al. 2014).  
In contrast to RCTs in prostate cancer that report PROs, risk of bias and quality of PRO reporting in colorectal cancer 
trials did not appear to be associated.  In CRC trials, approximately 50% of included studies with high quality PRO 
reporting demonstrated high risk of bias, compared to only 10-30% in prostate cancer(Efficace et al. 2013).  However, 
it was observed that reporting bias and selection bias was less common among RCTs with high quality PRO reporting 
compared to those with low quality reporting. The association between high quality reporting of PROs and a lower 
risk of selection bias may reflect improvements in trials practice and increased awareness of the issues relevant to 
trial design.  A further challenge facing open label studies, particularly those in surgery, is the risk of performance 
bias because of the difficulty in blinding participants to the intervention they received. Only a third of colorectal 
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cancer RCT’s identified in this review were at low risk of performance bias, however the effect of performance bias 
on clinical and particularly patient reported outcomes remains unclear and requires further evaluation.  
This review also identified studies with poor design which also introduces the risk of bias and it is recommended 
that recent SPIRIT guidance be used(Chan et al. 2013) when preparing the trial protocols to avoid poor design. 
However, it must be noted that the current SPIRIT statement does not specifically incorporate guidance regarding 
the design of trials that include PROs and it is further recommended that guidelines for PRO use should be 
incorporated into revisions of this statement. In addition trials should be reported according to CONSORT 
guidance(Moher et al. 2010) including its extension defining standards PRO reporting within RCT’s(Calvert et al. 
2013).. 
This review showed the important improvements in key PRO methodological aspects have occurred over time. For 
example, while clinical significance of PRO results was only addressed in 13% of studies published up to 2003, this 
has increased to almost a third in the current review. This suggests that while the current level of reporting is still 
suboptimal, improvements are occurring and should continue. A finding consistent with a recent review of PRO use 
in prostate cancer RCTs19. However, limitations persist in a number of areas of PRO reporting where current 
compliance to recommendations is poor. Specifically, future studies should pay particular attention to ensure RCTs 
define a schedule for PRO data collection, indicate an acceptable time window for questionnaire completion at each 
point in the study, document the reasons for missing data and particularly highlight the clinical significance of PRO 
data.   
In contrast to RCT’s in prostate cancer that report PROs(Efficace et al. 2013), the proportion of CRC trials with low 
risk of bias did not appear to be associated with the quality of PRO reporting.  Approximately half the studies in CRC 
treatment with good quality PRO were at high risk of bias whilst 10-30% of prostate cancers trials with high quality 
PRO reporting were affected by high risk of bias(Efficace et al. 2013) across most domains.  The exceptions were 
reporting bias (selective reporting) where the twice as many RCT’s with good quality PRO reporting (36%) were at 
low risk of bias when compared to studies with lower quality PRO reporting, and selection bias (allocation 
concealment) where low risk of bias was more common (61%) in studies with low quality PRO reporting. The 
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association between high quality reporting of PROs and a lower risk of selection bias may reflect improvements in 
trials practice and increased awareness of the issues relevant to trial design however the reasons for the association 
between lower risk of selection bias and lower quality PRO reporting is unclear. A further challenge facing open label 
studies, particularly those in surgery, is the risk of performance bias because of the difficulty in blinding participants 
to the intervention they received. Only a third of colorectal cancer RCT’s identified in this review were at low risk of 
performance bias, however the effect of performance bias on clinical and particularly patient reported outcomes 
remains unclear and requires further evaluation. 
This study has some limitations. Literature searches are imperfect and do risk omission of studies and studies in 
languages other than in English were excluded, although current evidence suggests this limitation does not 
significantly alter the conclusions of other systematic reviews(Juni et al. 2002; Moher et al. 2000). Additionally, the 
definition of high-quality reporting used was exclusively methodological and a strict approach when defining criteria 
necessary for a study to be classified as having high quality PRO methodology was adopted.  Although this resulted 
in fewer trials being classified as having high quality reporting, it was considered critical that high quality PRO 
methodology and reporting are promoted to ensure that trials results are robust and inform clinical practice. 
Strengths of this study included the rigorous and extensive searching of relevant databases, the use of a standardized 
approach to data validation which maintained data quality, the adoption of the highest quality criteria for assessing 
PROs and the use of face to face meetings when disagreement between reviewers occurred to reconcile differences 
until consensus on the extracted data was achieved   
 
To conclude, this review shows that only a fifth (13 studies; 20%) of RCTs describing treatments for 
colorectal cancer report PROs with high quality and are likely to robustly inform clinicians regarding the 
impact of treatments for CRC on PROs. Most studies do not provide sufficient information for clinicians or 
policy makers to appraise the results, and, whilst the reporting of certain specific criteria (e.g. clinical 
significance of the PRO findings) has improved with time, overall quality remains poor and risk of bias is 
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frequently high. In addition current research practice means that the time, effort and expertise of both 
patients and researchers are wasted and research funds are not optimally used.   
Therefore, we recommend that researchers and research funding bodies ensure strict  adherence to SPIRIT guidance 
(Chan et al. 2013) when preparing study protocols, ensure trial design minimizes the risk of bias and that the 
recommendations of the CONSORT guidance (Moher et al. 2010) including the PRO extension (Calvert et al. 2013) 
are applied by trialists and journal editors when reporting colorectal cancer trials. 
 
 
Acknowledgments 
This paper forms part of a larger project, the Patient Reported Outcome Measurements Over Time In ONcology-
PROMOTION Registry funded by a research grant from the European Organisation for Research and Treatment of 
Cancer (EORTC) Quality of Life Group. Also, additional support for the conduct of the study was provided by the 
Italian Group for Adult Hematologic Diseases (GIMEMA) and the MRC ConDuCT-II Hub for Trials Methodology 
Research in Bristol. We also acknowledge Alessandro Perreca and Salvatore Soldati, from the GIMEMA, for their 
contribution to data management. 
Conflict of Interest Statement: 
None  
 18 
 
Figure legends 
Figure 1 Schematic breakdown of literature search results of colorectal randomised controlled trials (Preferred 
Reporting Items for Systematic Reviews and Meta-analysis).  PRO= patient-reported outcomes. 
Figure 2 Risk bar chart showing proportion of studies with low, unclear or high risk of bias across all RCTs (n=66) by 
quality of PRO reporting. 
Figure 3  Descriptive comparison of level of reporting on selected key PRO issues in RCTs of colorectal describe 
both clinical and patient reported outcomes between 1980 and 2003 (yellow bars) (Efficace et al. 2003) and 2004 
and 2012 (blue bars). 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
 
References 
Bauhofer A et al. (2007) Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in 
high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial 
Surgery 141:501-510 doi:10.1016/j.surg.2006.09.004 
Brundage M et al. (2012) Patient-reported outcomes in randomized clinical trials: development of ISOQOL 
reporting standards Qual Life Res 22:1161-1175 doi:10.1007/s11136-012-0252-1 
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, Group CP (2013) Reporting of 
patient-reported outcomes in randomized trials: the CONSORT PRO extension Jama 309:814-822 
doi:10.1001/jama.2013.879 
Chan A-W et al. (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials 
BMJ 346 doi:10.1136/bmj.e7586 
Claassens L et al. (2011) Health-related quality of life in non-small-cell lung cancer: an update of a 
systematic review on methodologic issues in randomized controlled trials J Clin Oncol 29:2104-
2120 doi:10.1200/JCO.2010.32.3683 
Cocks K, King MT, Velikova G, Fayers PM, Brown JM (2008) Quality, interpretation and presentation of 
European Organisation for Research and Treatment of Cancer quality of life questionnaire core 
30 data in randomised controlled trials Eur J Cancer 44:1793-1798 doi:S0959-8049(08)00383-3 
[pii] 
10.1016/j.ejca.2008.05.008 
Coleman MP et al. (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 
1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based 
cancer registry data Lancet 377:127-138 doi:10.1016/S0140-6736(10)62231-3 
Coulman KD, Abdelrahman T, Owen-Smith A, Andrews RC, Welbourn R, Blazeby JM (2013) Patient-
reported outcomes in bariatric surgery: a systematic review of standards of reporting Obesity 
reviews : an official journal of the International Association for the Study of Obesity 
doi:10.1111/obr.12041 
Cunningham D et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus 
capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27:5513-5518 
doi:10.1200/JCO.2009.24.2446 
de Kort SJ, Willemse PHB, Habraken JM, de Haes HCJM, Willems DL, Richel DJ (2006) Quality of life versus 
prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A 
review of randomized controlled clinical trials European Journal of Cancer 42:835-845 
doi:http://dx.doi.org/10.1016/j.ejca.2005.10.026 
Denlinger CS, Barsevick AM (2009) The challenges of colorectal cancer survivorship Journal of the National 
Comprehensive Cancer Network : JNCCN 7:883-893; quiz 894 
Douillard JY et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, 
leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients 
with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28:4697-
4705 doi:10.1200/JCO.2009.27.4860 
Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'Haese S, Zurlo A (2003) Beyond the development 
of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in 
cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision 
making? J Clin Oncol 21:3502-3511 doi:10.1200/JCO.2003.12.121 
JCO.2003.12.121 [pii] 
 20 
 
Efficace F, Bottomley A, Vanvoorden V, Blazeby JM (2004) Methodological issues in assessing health-
related quality of life of colorectal cancer patients in randomised controlled trials Eur J Cancer 
40:187-197 
Efficace F et al. (2013) Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: 
Methodological Quality and Impact on Clinical Decision Making Eur Urol 
doi:10.1016/j.eururo.2013.10.017 
Greenhalgh J (2009) The applications of PROs in clinical practice: what are they, do they work, and why? 
Qual Life Res 18:115-123 doi:10.1007/s11136-008-9430-6 
Gujral S, Avery KN, Blazeby JM (2008) Quality of life after surgery for colorectal cancer: clinical implications 
of results from randomised trials Support Care Cancer 16:127-132 doi:10.1007/s00520-007-0356-
2 
Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, Orlando 
Higgins JPT GSe (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 
[updated March 2011]. The Cochrane Collaboration. doi:www.cochrane-handbook.org 
J F, HR S, F B, D F, C M, DM P (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC 
CancerBase No. 10. International Agency for Research on Cancer. http://globocan.iarc.fr. 
Accessed 23/10/2013 2013 
Janson M, Lindholm E, Anderberg B, Haglind E (2007) Randomized trial of health-related quality of life 
after open and laparoscopic surgery for colon cancer Surg Endosc 21:747-753 
doi:10.1007/s00464-007-9217-9 
Jonker DJ et al. (2007) Cetuximab for the treatment of colorectal cancer N Engl J Med 357:2040-2048 
doi:10.1056/NEJMoa071834 
Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-
analyses of controlled trials: empirical study Int J Epidemiol 31:115-123 
Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials J 
Clin Epidemiol 53:451-458 
Lembersky BC et al. (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil 
and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant 
Breast and Bowel Project Protocol C-06 J Clin Oncol 24:2059-2064 doi:10.1200/JCO.2005.04.7498 
Liberati A et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of 
studies that evaluate healthcare interventions: explanation and elaboration BMJ 339:b2700 
doi:10.1136/bmj.b2700 
Macefield RC, Avery KN, Blazeby JM (2013) Integration of clinical and patient-reported outcomes in 
surgical oncology Br J Surg 100:28-37 doi:10.1002/bjs.8989 
Macefield RC et al. (2014) Developing core outcomes sets: methods for identifying and including patient-
reported outcomes (PROs) Trials 15:49 doi:10.1186/1745-6215-15-49 
Main BG, Strong S, McNair AG, Falk SJ, Crosby T, Blazeby JM (2014) Reporting outcomes of definitive 
radiation-based treatment for esophageal cancer: a review of the literature Diseases of the 
esophagus : official journal of the International Society for Diseases of the Esophagus / ISDE 
doi:10.1111/dote.12168 
Moher D et al. (2010) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting 
parallel group randomised trials BMJ 340 doi:10.1136/bmj.c869 
Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, Liberati A (2000) What contributions do 
languages other than English make on the results of meta-analyses? J Clin Epidemiol 53:964-972 
Neoptolemos JP et al. (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine 
following pancreatic cancer resection: a randomized controlled trial Jama 304:1073-1081 
doi:10.1001/jama.2010.1275 
 21 
 
Odom D et al. (2011) Health-related quality of life and colorectal cancer-specific symptoms in patients 
with chemotherapy-refractory metastatic disease treated with panitumumab Int J Colorectal Dis 
26:173-181 doi:10.1007/s00384-010-1112-5 
Peeters KC et al. (2005) Late side effects of short-course preoperative radiotherapy combined with total 
mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch 
colorectal cancer group study J Clin Oncol 23:6199-6206 doi:10.1200/JCO.2005.14.779 
Peeters M et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and 
irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with 
metastatic colorectal cancer J Clin Oncol 28:4706-4713 doi:10.1200/JCO.2009.27.6055 
Richards DA et al. (2011) Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or 
metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study Invest New 
Drugs 29:144-153 doi:10.1007/s10637-009-9307-8 
Sibbald B, Roland M (1998) Understanding controlled trials: Why are randomised controlled trials 
important? BMJ 316:201 doi:10.1136/bmj.316.7126.201 
Staquet M, Berzon R, Osoba D, Machin D (1996) Guidelines for reporting results of quality of life 
assessments in clinical trials Qual Life Res 5:496-502 
Stephens RJ et al. (2010) Impact of short-course preoperative radiotherapy for rectal cancer on patients' 
quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada 
Clinical Trials Group C016 randomized clinical trial J Clin Oncol 28:4233-4239 
doi:10.1200/JCO.2009.26.5264 
Stucky CC et al. (2011) Long-term follow-up and individual item analysis of quality of life assessments 
related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146) Ann Surg Oncol 
18:2422-2431 doi:10.1245/s10434-011-1650-2 
Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV (2013) Quantifying fatigue in 
(long-term) colorectal cancer survivors: a study from the population-based patient reported 
outcomes following initial treatment and long term evaluation of survivorship registry Eur J 
Cancer 49:1957-1966 doi:10.1016/j.ejca.2013.01.012 
Tournier-Rangeard L et al. (2008) Radiochemotherapy of locally advanced anal canal carcinoma: 
prospective assessment of early impact on the quality of life (randomized trial ACCORD 03) 
Radiother Oncol 87:391-397 doi:10.1016/j.radonc.2007.12.004 
UK CR (2009) Bowel Cancer Incidence Statistics. 
http://info.cancerresearchuk.org/cancerstats/types/bowel/incidence/. Accessed 31/08/2012 
2012 
Ward JA, Potter S, Blazeby JM (2012) Outcome reporting for reconstructive breast surgery: the need for 
consensus, consistency and core outcome sets Eur J Surg Oncol 38:1020-1021 
doi:10.1016/j.ejso.2012.07.108 
Whistance RN, Blencowe NS, Blazeby JM (2012) The need for standardised outcome reporting in 
colorectal surgery Gut 61:472 doi:10.1136/gutjnl-2011-300676 
Whistance RN et al. (2013) A systematic review of outcome reporting in colorectal cancer surgery 
Colorectal Dis 15:e548-e560 doi:10.1111/codi.12378 
Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P (2012) Developing core 
outcome sets for clinical trials: issues to consider Trials 13:132 doi:10.1186/1745-6215-13-132 
 
 
